Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Grass Pollen Sublingual Immunotherapy in Children
NCT00841256Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Feb 2008
- Primary completion
- Jun 2012
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of allerslit forte in allergic rhinoconjunctivitis (ARC), sponsored by Allergopharma. Started Feb 2008; status: completed.
02
Drugs
allerslit forte
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00841256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841256.